Magazine article Risk Management

Johnson & Johnson Fined for Competitive Practices in France

Magazine article Risk Management

Johnson & Johnson Fined for Competitive Practices in France

Article excerpt

IN DECEMBER 2017, FRANCE'S COMPETITION AUTHORITY hit U.S. healthcare group Johnson & Johnson with a €25 million ($31 million) fine after it found that the company had deliberately slowed market access to generic copies of its painkiller, Durogesic, when its patent expired in 2005.

Durogesic is a skin patch often prescribed in cancer cases. It contains fentanyl, an opioid which, if misused, can lead to death by overdose.

According to France's Autorité de la Concurrence, Johnson & Johnson's subsidiary, Janssen-Cilag, had not only "repeatedly intervened" to block the approval processes in France of Durogesic's generic copies, but had also deliberately disparaged generics when in contact with doctors and other healthcare professionals, suggesting to the country's former agency for medical safety of health products (AFSSAPS) that generic versions of the drug were not "exactly similar" and that they were not subject to the same kind of quality or safety testing as the original version.

Janssen-Cilag instructed its medical sales teams to denigrate competing products, and specifically trained 300 sales representatives (called "commandos") to spread misinformation about the quality and safety of generic rivals. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.